Nasir Rajpoot

Histofy and Source BioScience Announce Strategic Partnership to Advance AI-Powered Pathology in the UK Coventry & Nottingham, UK (6 May 2025) — Histofy, a leading UK based pathology AI company focused on accelerating histopathology workflows in both clinical and pharmaceutical sectors, is proud to announce a strategic partnership with Source BioScience UK Limited, the largest histopathology service provider in the United Kingdom. This collaboration aims to accelerate the deployment of AI-driven diagnostics, improving accuracy, efficiency, and scalability of histopathological workflows. Through this strategic investment by Source BioScience into Histofy, the two companies will explore AI-based workflow efficiencies and integration of Histofy’s cutting-edge AI technology into Source BioScience’s state-of-the-art pathology laboratories. The initiative will firstly focus on enhancing laboratory workflows and accelerating diagnostic services, with a view to scaling AI-powered diagnostics across Source BioScience’s full range of laboratory services. Professor Nasir Rajpoot, CEO & CSO of Histofy, commented: “This is a major milestone for Histofy. Partnering with Source BioScience will enable our AI solutions to have a direct impact on patient care at scale, across one of the most trusted laboratory networks in the UK. Together, we are laying the foundation for the next generation of AI-enabled digital pathology services — ones that combine deep clinical expertise with cutting-edge artificial intelligence.” Jay LeCoque, CEO and Executive Chairman of Source BioScience, added: “Partnering with Histofy will allow us to accelerate our AI capabilities and improve our service offering to the NHS and private healthcare providers. Our combined goal is to improve patient care by providing much needed solutions for pathologists to fully engage AI as a widely accepted cancer detection and diagnostic tool.”       The partnership will also help improve operational efficiencies and create new business opportunities through AI-enabled services and clinical trial support. It also opens the door for R&D collaborations and co-development of new AI-enabled pathology assays. About Histofy Histofy is a UK-based pathology AI spinout from the University of Warwick that builds data-efficient transparent AI tools for histopathology. Its mission is to empower pathologists and healthcare providers with innovative software that accelerates pathologist decision-making and improves patient outcomes. About Source BioScience Source BioScience is an international provider of the state-of-the-art laboratory services, including digital pathology, diagnostics, clinical research services and genomics. With an expanding footprint of UKAS-accredited laboratories and a long-standing reputation for quality, Source BioScience supports both the NHS and private sector with quality-led laboratory services. For media inquiries, please contact Nasir Rajpoot at [email protected] or Klaudyna Johnstone at [email protected]

Histofy, a Birmingham-based startup, has been founded to accelerate the transformation of cancer research and care with cutting-edge transparent artificial intelligence (AI) technology. Birmingham, UK (6th February 2023) – Histofy AI, a UK-based startup, has been founded by a team of world leading experts with an accumulated 40+ years of experience in the field of digital pathology and AI. With over 250 publications in leading journals and conferences from research spanning over 20 years, the team brings their understanding of pathology and AI to  spearhead the development and introduction of advanced AI tools for clinical pathology and pharmaceutical research.  Transforming Pathology with AI Examination of pathology slides is essential in ensuring accurate diagnosis and appropriate treatment of many diseases, such as cancer. For many years, this has been done by visual inspection of the tissue with a microscope, but the digital pathology revolution means AI can be utilised to assist pathologists in delivering quicker and more accurate results – ultimately leading to better patient care.  Histofy has been launched to commercialise the AI tools the team has developed in research programmes over the past few years. This technology delivers transparent AI for deep profiling and interpretable decision-making from digitised images of pathology slides. “This is a very exciting time for pathology as we move into an era where pathologists will be using AI to assist in analysing patient tissue samples” Histofy Appoints CTO Today, Histofy also announces the appointment of Dr Simon Graham as the company’s Chief Technology Officer. With a background in mathematics and computer science, Dr Graham completed his PhD in computational pathology from the world-leading Tissue Image Analytics (TIA) Centre at the University of Warwick, where he was awarded the best thesis prize in the Faculty of Science, Engineering and Medicine.  Dr Graham, Chief Technology Officer at Histofy, said: “I am excited at the prospect of placing robust AI solutions in the hands of pathology and oncology researchers and practitioners to improve patient care. We are ready to make AI accessible across a range of solutions for the digital pathology market and believe that our technology will dramatically improve the management of diseases, such as cancer”.  Prof David Snead said:  “This is a very exciting time for pathology as we move into an era where pathologists will be using AI to assist in analysing patient tissue samples. Our research programme has developed some of the best and most interesting solutions. Histofy AI has been launched to take these technologies through productisation and commercialisation. Dr Simon Graham is a world leading computational pathology scientist developing this technology, so we are delighted to welcome him as our CTO.”